A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.

Hum Psychopharmacol · 2022 · PMC9286466 · PMID 34352138

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Zuranolone 30‐ and 45‐mg doses did not produce significant next‐day effects on sleepiness or psychomotor performance; however, KSS results showed a slight trend towards increased signs of sleepiness at the post‐PSG assessment in the zuranolone 45‐mg group.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.